NO20061655L - Behandling eller forebyggelse av restless legs syndron ved anvendelse av prodrug av GABA analoger - Google Patents

Behandling eller forebyggelse av restless legs syndron ved anvendelse av prodrug av GABA analoger

Info

Publication number
NO20061655L
NO20061655L NO20061655A NO20061655A NO20061655L NO 20061655 L NO20061655 L NO 20061655L NO 20061655 A NO20061655 A NO 20061655A NO 20061655 A NO20061655 A NO 20061655A NO 20061655 L NO20061655 L NO 20061655L
Authority
NO
Norway
Prior art keywords
prodrug
prevention
treatment
restless legs
legs syndrome
Prior art date
Application number
NO20061655A
Other languages
English (en)
Norwegian (no)
Inventor
Ronald William Barrett
Daniel M Canafax
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of NO20061655L publication Critical patent/NO20061655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20061655A 2003-09-17 2006-04-11 Behandling eller forebyggelse av restless legs syndron ved anvendelse av prodrug av GABA analoger NO20061655L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50417203P 2003-09-17 2003-09-17
US50472603P 2003-09-18 2003-09-18
US51227903P 2003-10-17 2003-10-17
US53849504P 2004-01-22 2004-01-22
PCT/US2004/030698 WO2005027850A2 (en) 2003-09-17 2004-09-17 Treating or preventing restless legs syndrome using prodrugs of gaba analogs

Publications (1)

Publication Number Publication Date
NO20061655L true NO20061655L (no) 2006-06-15

Family

ID=34382174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061655A NO20061655L (no) 2003-09-17 2006-04-11 Behandling eller forebyggelse av restless legs syndron ved anvendelse av prodrug av GABA analoger

Country Status (15)

Country Link
US (1) US8114909B2 (zh)
EP (1) EP1677812A4 (zh)
JP (1) JP5107576B2 (zh)
KR (1) KR101157436B1 (zh)
CN (1) CN1871021B (zh)
AU (1) AU2004274002B2 (zh)
BR (1) BRPI0414481A (zh)
CA (1) CA2538802C (zh)
IL (2) IL174282A (zh)
MX (1) MXPA06003043A (zh)
NO (1) NO20061655L (zh)
NZ (2) NZ579515A (zh)
SG (1) SG146643A1 (zh)
WO (1) WO2005027850A2 (zh)
ZA (1) ZA200602182B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
AU2004272111A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
BRPI0415288B8 (pt) * 2003-10-14 2021-05-25 Xenoport Inc composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
US7330122B2 (en) 2005-08-10 2008-02-12 Remotemdx, Inc. Remote tracking and communication device
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
US7737841B2 (en) 2006-07-14 2010-06-15 Remotemdx Alarm and alarm management system for remote tracking devices
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20090041806A1 (en) * 2007-06-15 2009-02-12 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
EP2192916A4 (en) * 2007-08-23 2012-04-04 Univ Leland Stanford Junior MODULATION OF SYNAPTOGENESIS
TWI380812B (zh) * 2008-01-25 2013-01-01 Xenoport Inc （３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2010017504A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
KR20110124338A (ko) * 2009-03-02 2011-11-16 아스텔라스세이야쿠 가부시키가이샤 고형 제제의 포장체
EP2403486A1 (en) * 2009-03-03 2012-01-11 XenoPort, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
KR20110126747A (ko) * 2009-03-06 2011-11-23 제노포트 인코포레이티드 고용량의 가바펜틴 프로드러그를 갖는 경구 투여 제형
EP2961730A2 (en) 2013-02-26 2016-01-06 XenoPort, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds
CN105169266A (zh) * 2015-10-02 2015-12-23 陈爱华 一种用于治疗不安腿综合征的药物制剂
CN105777586A (zh) * 2016-04-14 2016-07-20 安徽省逸欣铭医药科技有限公司 S（+）氨己烯酸酯衍生物及其制备方法和用途
AU2019221886A1 (en) 2018-02-15 2020-10-01 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
WO2020165633A1 (en) * 2019-02-11 2020-08-20 Glenmark Pharmaceuticals Limited A pharmaceutical composition of gabapentin enacarbil or salt thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084169A (en) * 1989-09-19 1992-01-28 The University Of Colorado Foundation, Inc. Stationary magnetically stabilized fluidized bed for protein separation and purification
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1993023383A1 (en) 1992-05-20 1993-11-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
PL328432A1 (en) 1996-02-07 1999-02-01 Warner Lambert Co Novel cyclic amino acids as pharmaceutic agents
KR100512506B1 (ko) 1996-03-14 2005-12-21 워너-램버트 캄파니 엘엘씨 제약제제로서신규한치환시클릭아미노산
NZ331142A (en) 1996-03-14 2001-04-27 Warner Lambert Co Bridged cyclic amino acids as pharmaceutical agents
BR9710536A (pt) * 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
US6375987B1 (en) * 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
NZ334898A (en) 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
SE509618C2 (sv) 1997-03-06 1999-02-15 Goeran Blomqvist Farmaceutisk komposition för behandling av s k restless legs
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
CN1303059C (zh) 1997-10-27 2007-03-07 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物
CN1279667A (zh) 1997-12-16 2001-01-10 沃尼尔·朗伯公司 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
JP2002508362A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
US6521650B1 (en) 1997-12-16 2003-02-18 Pfizer, Inc. Amines as pharmaceutical agents
AU2463099A (en) 1998-01-23 1999-08-09 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
CZ297284B6 (cs) 1998-03-27 2006-10-11 Pharmacia & Upjohn Company Farmaceutiký prostredek pro lécbu syndromu neklidných nohou
US6316638B1 (en) 1998-05-26 2001-11-13 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
AUPP396998A0 (en) 1998-06-09 1998-07-02 University Of Melbourne, The A method for increasing the permeability of wood
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
CA2339273C (en) 1998-09-14 2005-10-18 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids
ES2279631T3 (es) 1998-10-16 2007-08-16 Warner-Lambert Company Llc Uso de analogos de gaba para la fabricaion de un medicamento para el tratamiento de mania y trastornos bipolares.
US6627771B1 (en) 1998-11-25 2003-09-30 Pfizer Inc Gamma amino butyric and acid analogs
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
NZ517044A (en) * 1999-07-22 2004-02-27 Univ Rochester Gamma-aminobutyric acid analogues, e.g. gabapentin and pregabalin, to treat symptoms of hormonal variation, including hot flushes, nausea, emesis and fever
JP2003523405A (ja) * 2000-02-22 2003-08-05 セレジー カナダ インコーポレイテッド 睡眠改善のための方法および組成物
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
DK1296671T3 (da) 2000-06-26 2008-06-16 Warner Lambert Co Gabapentinanaloger til sövnforstyrrelser
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
DE10043321B4 (de) 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
WO2002042414A2 (en) 2000-11-17 2002-05-30 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2002069974A1 (en) 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345638A1 (en) 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
AU2002316237A1 (en) 2001-06-13 2002-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain
WO2003026676A1 (en) 2001-09-24 2003-04-03 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
HUP0401967A2 (hu) 2001-10-31 2005-01-28 Pfizer Products Inc. Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
TW555626B (en) * 2003-01-24 2003-10-01 Smoos Tool Co Ltd Method for treating a collar surface and its product
BRPI0415288B8 (pt) * 2003-10-14 2021-05-25 Xenoport Inc composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
CA2584338C (en) * 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms

Also Published As

Publication number Publication date
IL174282A (en) 2012-12-31
JP2007511464A (ja) 2007-05-10
JP5107576B2 (ja) 2012-12-26
EP1677812A2 (en) 2006-07-12
CN1871021B (zh) 2010-07-28
US20050192353A1 (en) 2005-09-01
MXPA06003043A (es) 2006-05-31
WO2005027850A3 (en) 2005-06-16
AU2004274002B2 (en) 2011-04-28
IL174282A0 (en) 2006-08-01
KR101157436B1 (ko) 2012-07-05
SG146643A1 (en) 2008-10-30
NZ545989A (en) 2009-10-30
IL200687A0 (en) 2011-08-01
NZ579515A (en) 2011-09-30
CA2538802A1 (en) 2005-03-31
ZA200602182B (en) 2012-07-25
KR20060106815A (ko) 2006-10-12
BRPI0414481A (pt) 2006-11-14
CN1871021A (zh) 2006-11-29
EP1677812A4 (en) 2010-03-24
WO2005027850A2 (en) 2005-03-31
AU2004274002A1 (en) 2005-03-31
CA2538802C (en) 2015-01-27
US8114909B2 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
NO20061655L (no) Behandling eller forebyggelse av restless legs syndron ved anvendelse av prodrug av GABA analoger
NO20061625L (no) Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger
NO20055000L (no) Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
ATE555810T1 (de) Mittel zur behandlung oder prävention von verdauungsgeschwüren
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
NO20064584L (no) Tetrahydropyridoindolderivater
MX338530B (es) Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
DK1611088T3 (da) Hydroxymater som terapeutiske midler
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
EA200900258A1 (ru) Ингибиторы растворимой эпоксидгидролазы, фармацевтическая композиция на их основе и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
DE602005024571D1 (de) Opioide zur behandlung von ruhelosigkeit in den unteren gliedmassen
DK1957061T3 (da) Kombination omfattende mindst én aminosyre og en PKR-inhibitor til anvendelse i behandlingen af muskelsvind
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
NO20063842L (no) Silinanforbindelser som cysteinproteaseinhibitorer
WO2007027477A3 (en) Treating vulvodynia using prodrugs of gaba analogs
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
NO20064753L (no) Kombinasjonsterapi
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application